Released Aug 8, 2024, after the close
10-Q filed Aug 8, 2024, 39 days after period end · 0001628280-24-036231
Q2 2024 · 10-Q
Revenue$56.21M$56.21M −30.2% vs Q2 2023+48.1% vs Q1 2024
Net Income-$217.18M-$217.18M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$4.23-$4.23 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$222,945,000N/M
Operating Cash Flowderived-$84,390,000N/M
Free Cash Flowderived-$111,422,000N/M
Margins · derived
Operating margin-396.7%−168.1 pt vs Q2 2023
Net margin-386.4%−171.3 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $56.21M | $80.57M | $144.62M | $43.64M |
| Net Income | -$217.18M | -$173.32M | -$668.83M | -$53.94M |
| EPS Diluted | -$4.23 | -$0.09 | -$0.41 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR